Selenium supplementation and colorectal adenomas

An analysis of the nutritional prevention of cancer trial

Mary E. Reid, Anna J. Duffield-Lillico, Annette Sunga, Marwan Fakih, David S Alberts, James R. Marshall

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Selenium status has been inversely associated with colorectal cancers (CRC) and adenomas. This investigation evaluates the association between selenium supplementation and prevalent and incident colorectal adenomas and CRC detected during the Nutritional Prevention of Cancer trial follow-up. Of the 1,312 randomized to 200 meg of selenized yeast of matching placebo, 598 participants underwent endoscopic screening (flexible sigmoidoscopy or colonoscopy) for CRC sometime during the follow-up period, which ended in February 1, 1996. There was no colorectal screening performed at baseline. Of those screened, 77% were male (with a mean age of 62.8 years), 42% were former and 25% were current smokers. Adenomas were classified as prevalent (identified at the first endoscopic examination postrandomization during the follow-up period) or incident (identified at the second or subsequent examination). Ninety-nine prevalent and 61 incident adenomas were ascertained. Logistic regression odds ratios (OR) and 95% confidence intervals (CI) were calculated, adjusting for age, gender and smoking status. For prevalent adenomas, there was a suggestive but nonsignificant decrease in risk associated with selenium treatment (OR = 0.67, 95% CI = 0.43-1.05). Subjects in the lowest tertile of baseline selenium (OR = 0.27, 95% CI = 0.09-0.77) and current smokers (OR = 0.27, 95% CI = 0.11-0.66) had significant reductions in risk. The OR for incident adenomas was 0.98 (95% CI = 0.57-1.68). In addition to being associated with a reduced risk of incident CRC, selenium supplementation was associated with a significantly reduced risk of prevalent adenomas, but only among subjects with either a low baseline selenium level or among current smokers.

Original languageEnglish (US)
Pages (from-to)1777-1781
Number of pages5
JournalInternational Journal of Cancer
Volume118
Issue number7
DOIs
StatePublished - Apr 1 2006

Fingerprint

Selenium
Adenoma
Odds Ratio
Confidence Intervals
Colorectal Neoplasms
Neoplasms
Sigmoidoscopy
Risk Reduction Behavior
Colonoscopy
Yeasts
Logistic Models
Smoking
Placebos

Keywords

  • Colorectal adenomas
  • Colorectal cancer
  • Selenium

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Selenium supplementation and colorectal adenomas : An analysis of the nutritional prevention of cancer trial. / Reid, Mary E.; Duffield-Lillico, Anna J.; Sunga, Annette; Fakih, Marwan; Alberts, David S; Marshall, James R.

In: International Journal of Cancer, Vol. 118, No. 7, 01.04.2006, p. 1777-1781.

Research output: Contribution to journalArticle

Reid, Mary E. ; Duffield-Lillico, Anna J. ; Sunga, Annette ; Fakih, Marwan ; Alberts, David S ; Marshall, James R. / Selenium supplementation and colorectal adenomas : An analysis of the nutritional prevention of cancer trial. In: International Journal of Cancer. 2006 ; Vol. 118, No. 7. pp. 1777-1781.
@article{3cb80de2caca4a8e96086f9d479ae245,
title = "Selenium supplementation and colorectal adenomas: An analysis of the nutritional prevention of cancer trial",
abstract = "Selenium status has been inversely associated with colorectal cancers (CRC) and adenomas. This investigation evaluates the association between selenium supplementation and prevalent and incident colorectal adenomas and CRC detected during the Nutritional Prevention of Cancer trial follow-up. Of the 1,312 randomized to 200 meg of selenized yeast of matching placebo, 598 participants underwent endoscopic screening (flexible sigmoidoscopy or colonoscopy) for CRC sometime during the follow-up period, which ended in February 1, 1996. There was no colorectal screening performed at baseline. Of those screened, 77{\%} were male (with a mean age of 62.8 years), 42{\%} were former and 25{\%} were current smokers. Adenomas were classified as prevalent (identified at the first endoscopic examination postrandomization during the follow-up period) or incident (identified at the second or subsequent examination). Ninety-nine prevalent and 61 incident adenomas were ascertained. Logistic regression odds ratios (OR) and 95{\%} confidence intervals (CI) were calculated, adjusting for age, gender and smoking status. For prevalent adenomas, there was a suggestive but nonsignificant decrease in risk associated with selenium treatment (OR = 0.67, 95{\%} CI = 0.43-1.05). Subjects in the lowest tertile of baseline selenium (OR = 0.27, 95{\%} CI = 0.09-0.77) and current smokers (OR = 0.27, 95{\%} CI = 0.11-0.66) had significant reductions in risk. The OR for incident adenomas was 0.98 (95{\%} CI = 0.57-1.68). In addition to being associated with a reduced risk of incident CRC, selenium supplementation was associated with a significantly reduced risk of prevalent adenomas, but only among subjects with either a low baseline selenium level or among current smokers.",
keywords = "Colorectal adenomas, Colorectal cancer, Selenium",
author = "Reid, {Mary E.} and Duffield-Lillico, {Anna J.} and Annette Sunga and Marwan Fakih and Alberts, {David S} and Marshall, {James R.}",
year = "2006",
month = "4",
day = "1",
doi = "10.1002/ijc.21529",
language = "English (US)",
volume = "118",
pages = "1777--1781",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "7",

}

TY - JOUR

T1 - Selenium supplementation and colorectal adenomas

T2 - An analysis of the nutritional prevention of cancer trial

AU - Reid, Mary E.

AU - Duffield-Lillico, Anna J.

AU - Sunga, Annette

AU - Fakih, Marwan

AU - Alberts, David S

AU - Marshall, James R.

PY - 2006/4/1

Y1 - 2006/4/1

N2 - Selenium status has been inversely associated with colorectal cancers (CRC) and adenomas. This investigation evaluates the association between selenium supplementation and prevalent and incident colorectal adenomas and CRC detected during the Nutritional Prevention of Cancer trial follow-up. Of the 1,312 randomized to 200 meg of selenized yeast of matching placebo, 598 participants underwent endoscopic screening (flexible sigmoidoscopy or colonoscopy) for CRC sometime during the follow-up period, which ended in February 1, 1996. There was no colorectal screening performed at baseline. Of those screened, 77% were male (with a mean age of 62.8 years), 42% were former and 25% were current smokers. Adenomas were classified as prevalent (identified at the first endoscopic examination postrandomization during the follow-up period) or incident (identified at the second or subsequent examination). Ninety-nine prevalent and 61 incident adenomas were ascertained. Logistic regression odds ratios (OR) and 95% confidence intervals (CI) were calculated, adjusting for age, gender and smoking status. For prevalent adenomas, there was a suggestive but nonsignificant decrease in risk associated with selenium treatment (OR = 0.67, 95% CI = 0.43-1.05). Subjects in the lowest tertile of baseline selenium (OR = 0.27, 95% CI = 0.09-0.77) and current smokers (OR = 0.27, 95% CI = 0.11-0.66) had significant reductions in risk. The OR for incident adenomas was 0.98 (95% CI = 0.57-1.68). In addition to being associated with a reduced risk of incident CRC, selenium supplementation was associated with a significantly reduced risk of prevalent adenomas, but only among subjects with either a low baseline selenium level or among current smokers.

AB - Selenium status has been inversely associated with colorectal cancers (CRC) and adenomas. This investigation evaluates the association between selenium supplementation and prevalent and incident colorectal adenomas and CRC detected during the Nutritional Prevention of Cancer trial follow-up. Of the 1,312 randomized to 200 meg of selenized yeast of matching placebo, 598 participants underwent endoscopic screening (flexible sigmoidoscopy or colonoscopy) for CRC sometime during the follow-up period, which ended in February 1, 1996. There was no colorectal screening performed at baseline. Of those screened, 77% were male (with a mean age of 62.8 years), 42% were former and 25% were current smokers. Adenomas were classified as prevalent (identified at the first endoscopic examination postrandomization during the follow-up period) or incident (identified at the second or subsequent examination). Ninety-nine prevalent and 61 incident adenomas were ascertained. Logistic regression odds ratios (OR) and 95% confidence intervals (CI) were calculated, adjusting for age, gender and smoking status. For prevalent adenomas, there was a suggestive but nonsignificant decrease in risk associated with selenium treatment (OR = 0.67, 95% CI = 0.43-1.05). Subjects in the lowest tertile of baseline selenium (OR = 0.27, 95% CI = 0.09-0.77) and current smokers (OR = 0.27, 95% CI = 0.11-0.66) had significant reductions in risk. The OR for incident adenomas was 0.98 (95% CI = 0.57-1.68). In addition to being associated with a reduced risk of incident CRC, selenium supplementation was associated with a significantly reduced risk of prevalent adenomas, but only among subjects with either a low baseline selenium level or among current smokers.

KW - Colorectal adenomas

KW - Colorectal cancer

KW - Selenium

UR - http://www.scopus.com/inward/record.url?scp=33644857488&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644857488&partnerID=8YFLogxK

U2 - 10.1002/ijc.21529

DO - 10.1002/ijc.21529

M3 - Article

VL - 118

SP - 1777

EP - 1781

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 7

ER -